Susquehanna International Group’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Susquehanna International Group’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,607	Closed	-$102K	–	13353
2024 Q2	$102K	Sell	11,607 -5,824	-33%	-$51.6K	﹤0.01%	11020
2024 Q1	$153K	Buy	17,431 +1,860	+12%	+$15.3K	﹤0.01%	10889
2023 Q4	$116K	Buy	15,571 +3,405	+28%	+$22.2K	﹤0.01%	11207
2023 Q3	$70K	Buy	12,166 +11,468	+1,643%	+$78.4K	﹤0.01%	11135
2023 Q2	$5.03K	Buy	+698	New	+$5.07K	﹤0.01%	11828
2023 Q1	–	Sell	-1,294	Closed	-$8.64K	–	13714
2022 Q4	$8.64K	Buy	+1,294	New	+$11.3K	﹤0.01%	11959
2022 Q3	–	Sell	-834	Closed	-$10K	–	14345
2022 Q2	$10K	Buy	834 +114	+16%	+$1.8K	﹤0.01%	12512
2022 Q1	$15K	Sell	720 -94	-12%	-$3.25K	﹤0.01%	12693
2021 Q4	$49K	Buy	+814	New	+$60.9K	﹤0.01%	12561

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Susquehanna International Group's TLIS Position: Q3 2024 in Review

Susquehanna International Group sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 11,607 shares — an estimated $102K sold.

Susquehanna International Group first reported a position in TLIS in Q4 2021 and held it in 9 quarters. The position peaked at $153K in Q1 2024. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

Susquehanna International Group reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
Susquehanna International Group sold 11,607 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $102K.
Susquehanna International Group first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and held it in 9 quarters.
Susquehanna International Group's Talis Biomedical Corporation Common Stock position peaked at $153K in Q1 2024.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.